Bright Peak Therapeutics

What Bright Peak Therapeutics does

Bright Peak Therapeutics is a privately held, clinical-stage biotechnology company founded in 2017/2018 by Vijaya Pattabiraman and Jeffrey Bode out of ETH Zurich, headquartered in Allschwil, Switzerland with US operations in Del Mar/San Diego, California. The company is developing a portfolio of next-generation multifunctional precision immunotherapies for the treatment of cancer and autoimmune diseases, anchored by its proprietary EDC (Engineered Donor Acceptor) chemical ligation platform that enables site-specific protein modification and construction of multi-mechanism biologics. Its lead clinical candidate, BPT567, is a first-in-class PD1-IL18 immunoconjugate that combines PD-1 checkpoint blockade with targeted IL-18 cytokine delivery in a single molecule, and entered a Phase 1/2a clinical trial for solid tumors in late 2024.

The company is backed by a top-tier syndicate of life sciences investors and has raised approximately $232 million across a Series A (2020, $35M, led by Versant Ventures), Series B (2021, $107M, led by RA Capital), and Series C (2024, $90M, led by Johnson & Johnson Innovation – JJDC). Bright Peak is led by President & CEO Fredrik Wiklund, whose prior track record includes biotech IPOs at Celladon and Tercica and ~$1.15 billion in aggregate prior M&A transactions, and President of R&D Jon Wigginton MD, who previously led early clinical development of nivolumab/opdivo and the broader BMS immuno-oncology portfolio.

Bright Peak operates a pre-revenue business model typical of clinical-stage biotechs: it does not currently sell commercial products, has not disclosed pricing, and finances operations exclusively through equity capital. Its addressable end customers are oncology patients with solid tumors and patients with autoimmune diseases, served through pharmaceutical distribution channels post any future regulatory approval; today its investor base and strategic partners effectively substitute for customers, with Johnson & Johnson's strategic venture arm anchoring the latest financing round.

Name

Bright Peak Therapeutics

Legal name

Bright Peak Therapeutics AG

Website

https://brightpeaktx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Bright Peak Therapeutics is a privately held, clinical-stage biotechnology company developing multifunctional precision immunotherapies for cancer and autoimmune diseases using its proprietary EDC chemical ligation platform, with lead candidate BPT567, a first-in-class PD1-IL18 immunoconjugate, in a Phase 1/2a trial for solid tumors.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

Keywords

• Cancer immunotherapy
• Immunoconjugate therapeutics
• Protein engineering platform
• Cytokine immunotherapy
• Oncology biologics

Headquarters

HQ city

Allschwil

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels1 record

Core offering

Bright Peak Therapeutics develops next-generation multifunctional precision immunotherapies for cancer and autoimmune diseases using its proprietary EDC chemical ligation protein-engineering platform. Its lead product, BPT567, is a first-in-class PD1-IL18 immunoconjugate that combines PD-1 checkpoint blockade with targeted IL-18 cytokine delivery in a single therapeutic molecule and is currently in Phase 1/2a clinical trials for solid tumors.

Product overview

Bright Peak Therapeutics is developing a portfolio of next-generation multi-functional immunotherapies using its proprietary protein engineering platform. The lead product is BPT567, a first-in-class PD1-IL18 immunoconjugate for solid tumors. The company is leveraging its cytokine immunotherapy platform to develop treatments for cancer and autoimmune diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• BPT567 BPT567 is Bright Peak's first-in-class PD1-IL18 immunoconjugate designed for the treatment of solid tumors. It combines PD-1 checkpoint blockade with targeted IL-18 cytokine delivery in a single therapeutic molecule and is currently in Phase 1/2a clinical trials. The candidate is intended for cancer patients with solid tumors, particularly those resistant to existing checkpoint inhibitors.

Quantifiable outcome

• Phase 1/2a clinical trial for BPT567 in solid tumors initiated in late 2024

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting with immune agonists. Most directly comparable to Bright Peak's approach of fusing immune-engaging payloads (IL-18) to targeting moieties (PD-1) in a single multifunctional molecule.
• Werewolf Therapeutics: Clinical-stage biotech with a proprietary INDUKINE platform that designs conditionally activated cytokine prodrugs for cancer immunotherapy. Directly comparable to Bright Peak's cytokine-based immunoconjugate approach, both companies engineer cytokines for improved therapeutic index in oncology.
• Cullinan Oncology: Clinical-stage immuno-oncology company developing multiple programs including cytokine-based therapies and checkpoint combinations. Highly comparable as a similarly-staged, publicly-traded clinical biotech with overlapping immuno-oncology focus; additionally, Jon Wigginton (Bright Peak's R&D President) was previously CMO at Cullinan.
• Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies for oncology, including a PD-1/PD-L1 bispecific (CTX-112) and other checkpoint-engaging molecules. Comparable in developing multifunctional immune-engaging antibody-based therapeutics for solid tumors.
• CytomX Therapeutics: Clinical-stage biotech with a Probody platform that uses masked/conditionally-activated antibodies for cancer. Comparable in developing engineered protein therapeutics designed to improve tumor selectivity and therapeutic index, though focused on masking rather than cytokine conjugation.
• Pyxis Oncology: Clinical-stage biotech developing antibody-drug conjugates and immunotherapies for cancer. Comparable as a similarly-staged biotech developing multifunctional antibody-based oncology therapeutics, with overlapping investor syndicate (RA Capital, Bayer).
• Janux Therapeutics: Clinical-stage biotech developing bispecific T-cell engagers for solid tumors. Comparable as a similarly-staged clinical biotech developing engineered multifunctional antibody constructs for oncology, with overlapping strategic investor interest (RA Capital).
• Harpoon Therapeutics: Clinical-stage biotech developing T-cell engagers (acquired by Merck in 2024 for ~$680M). Comparable as a developer of engineered multifunctional immune-engaging antibody therapeutics for solid tumors; provides a relevant M&A comp for Bright Peak given Merck/J&J strategic interest.

Broad incumbents

• Roche (Genentech): Large pharma with approved checkpoint inhibitor Tecentriq (anti-PD-L1) and extensive immuno-oncology pipeline including cytokine-based combinations and bispecifics. Relevant incumbent competing in Bright Peak's PD-1/IL-18 space with substantially greater resources.
• Bristol Myers Squibb: Large pharma with Opdivo (PD-1 inhibitor) approved and extensive checkpoint inhibitor/cytokine combination programs. Relevant incumbent and direct competitor; notably, Bright Peak's R&D President Jon Wigginton previously led early clinical development of Opdivo at BMS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bright-peak-therapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bright Peak Therapeutics